Exendins are glucagon-like peptide-1 (GLP-1) receptor agonists with a greater resistance to dipeptidyl peptidase-IV degradation, a longer half-life, and are more potent in vivo activity than native GLP-1. Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting injectable agent, major approaches have focused on developing long-acting exendin analogs to improve patient compliance and convenience.
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015) | Request PDF. Available from: Visit Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015) | Request PDF to see more.